DENTSPLY SIRONA Inc. designs, develops, manufactures, distributes, and sells various dental products and technologies primarily for professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression and restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers. The company also offers dental laboratory products, such as dental prosthetics that include artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials; and laboratory-based CAD/CAM milling systems, amalgamators, mixing machines, and porcelain furnaces. In addition, it provides dental technology products, including dental implants and related scanning equipment, and treatment software; orthodontic clear aligners and appliances for dental practitioners and specialist; and dental equipment, such as treatment centers, imaging equipment, dental handpieces, and computer aided design and machining systems for dental practitioners. Further, the company offers healthcare consumable products, such as urology catheters, medical drills, and other non-medical products. It markets and sells dental products through distributors, dealers, and importers; dental hygienists, assistants, laboratories, and schools; and urology products directly to patients, as well as through distributors to urologists, continence care nurses, general practitioners, and direct-to-patients. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1899 and is headquartered in Charlotte, North Carolina.
IPO Year: 1987
Exchange: NASDAQ
Website: dentsplysirona.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2025 | $12.00 | Underweight | Barclays |
| 11/7/2025 | Outperform → Mkt Perform | William Blair | |
| 4/15/2025 | $14.00 | Overweight → Equal-Weight | Morgan Stanley |
| 3/13/2025 | Buy → Hold | Needham | |
| 2/14/2025 | $20.00 | Equal Weight | Wells Fargo |
| 1/23/2025 | $30.00 → $20.00 | Buy → Hold | Jefferies |
| 1/7/2025 | $20.00 | Outperform → In-line | Evercore ISI |
| 12/4/2024 | $21.00 | Neutral | Mizuho |
| 11/7/2024 | Outperform → Market Perform | Leerink Partners | |
| 10/25/2024 | $34.00 → $29.00 | Buy | Needham |
8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
SCHEDULE 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
8-K/A - DENTSPLY SIRONA Inc. (0000818479) (Filer)
10-Q - DENTSPLY SIRONA Inc. (0000818479) (Filer)
8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4/A - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
Fastest customizable press release news feed in the world
CHARLOTTE, N.C., Jan. 14, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona") (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, and Patterson Dental Holdings ("Patterson Dental"), a leading supplier of products and services to the dental and animal health end markets, today announced the renewal of their U.S. dental technology distribution agreement. This renewed partnership reflects both companies' commitment to supporting dental professionals with advanced technologies and expert service while setting a clear focus on driving growth and innovation in the years ahead. A Partnership Focused on the Future Dentsply S
Benco Dental will offer Dentsply Sirona's full portfolio of dental technology solutions, in addition to the consumables portfolio. Expanding the decades-long relationship reflects a shared vision to advance connected dentistry by facilitating access to an integrated ecosystem that connects devices, software, and people—from scanning to designing and manufacturing—for greater efficiency and better patient outcomes. CHARLOTTE, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona") (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, and Benco Dental, the nation's largest family-owned dental company, announced
CHARLOTTE, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointment of Donald (Don) Zurbay to its Board of Directors (the "Board"), effective January 10, 2026. He will be joining the Board's Audit and Finance Committee. Mr. Zurbay brings extensive leadership experience in the dental and healthcare industries, and value creation across complex, global organizations. He most recently served as President and Chief Executive Officer (CEO) of Patterson Companies, following his tenure as Chief Financial Officer (CFO) from 2018 to 2022. During his tenure, Patterson maintained a longstanding dealer partnership
CHARLOTTE, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced the appointment of Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization, effective January 28. The appointment supports Dentsply Sirona's continued focus on strengthening commercial execution, deepening customer relationships and accelerating growth across the Americas. Mr. Bezjak is a seasoned commercial executive with more than 20 years of experience leading large-scale, multi-billion-dollar organizations in the medical device
CHARLOTTE, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 3:00 p.m. PT (6:00 p.m. ET). During the presentation, Dan Scavilla, President and CEO of Dentsply Sirona, will provide an update on the Company's differentiated Connected Dentistry portfolio, dental market trends and the Company's progress against its return-to-growth strategy. Investors and other interested parties will be able to access a live audio webcast and audio webcast replay by visiting the Investors section
CHARLOTTE, N.C., Dec. 15, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on January 9, 2026, to holders of record as of December 26, 2025. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including den
Dentsply Sirona Reports Third Quarter 2025 Results Net sales of $904 million decreased (5.0%) as-reported, decreased (8.0%) in constant currency including (5.5%) driven by Q3 2024 Byte impact and ERP pre-buyGAAP gross margin of 48.8%, GAAP net loss per share of ($2.14)Adjusted gross margin of 52.6%, adjusted EBITDA margin of 18.4%, adjusted EPS of $0.37Revised FY25 outlook Executing its Return-to-Growth action plan to drive improved performance and deliver sustained, profitable growthProvides leadership updates to support transformation strategy CHARLOTTE, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its f
CHARLOTTE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, November 6, 2025, at 8:30 am ET to review its financial results for the third quarter of fiscal year 2025. The Company will issue a press release and provide a presentation with summary financial information, which will be made available on the Investors section of the Company's website at https://investor.dentsplysirona.com prior to the call. Conference Call / Webcast Information The live webcast will be available on the Investors section of the Company's website at
CHARLOTTE, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Aldo M. Denti has been appointed Executive Vice President and Chief Commercial Officer (CCO), effective October 6, 2025. The appointment is designed to sharpen the Company's focus on the customer by aligning its Global Business Units and Commercial Organizations more closely - streamlining how Dentsply Sirona works and delivers. Mr. Denti is a global business leader with over 25 years of experience driving transformative growth in the Medical Device and Consumer Health sectors. His expertise spans sales, marketing, strategic planning, and successf
CHARLOTTE, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company has completed the evaluation of strategic alternatives for its Wellspect Healthcare business ("Wellspect"), which was announced in February 2025. As a part of its review process, Dentsply Sirona considered a range of potential opportunities for Wellspect, including a sale of the business. The Company conducted broad outreach, including engaging with multiple parties regarding their interest in Wellspect. Following extensive review and deliberation, Dentsply Sirona determined that retaining Wellspect as a subsidiary within its portfoli
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Barclays initiated coverage of Dentsply Sirona with a rating of Underweight and set a new price target of $12.00
William Blair downgraded Dentsply Sirona from Outperform to Mkt Perform
Morgan Stanley downgraded Dentsply Sirona from Overweight to Equal-Weight and set a new price target of $14.00
Needham downgraded Dentsply Sirona from Buy to Hold
Wells Fargo initiated coverage of Dentsply Sirona with a rating of Equal Weight and set a new price target of $20.00
Jefferies downgraded Dentsply Sirona from Buy to Hold and set a new price target of $20.00 from $30.00 previously
Evercore ISI downgraded Dentsply Sirona from Outperform to In-line and set a new price target of $20.00
Mizuho initiated coverage of Dentsply Sirona with a rating of Neutral and set a new price target of $21.00
Leerink Partners downgraded Dentsply Sirona from Outperform to Market Perform
Needham reiterated coverage of Dentsply Sirona with a rating of Buy and set a new price target of $29.00 from $34.00 previously
This live feed shows all institutional transactions in real time.
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
Live Leadership Updates
CHARLOTTE, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointment of Donald (Don) Zurbay to its Board of Directors (the "Board"), effective January 10, 2026. He will be joining the Board's Audit and Finance Committee. Mr. Zurbay brings extensive leadership experience in the dental and healthcare industries, and value creation across complex, global organizations. He most recently served as President and Chief Executive Officer (CEO) of Patterson Companies, following his tenure as Chief Financial Officer (CFO) from 2018 to 2022. During his tenure, Patterson maintained a longstanding dealer partnership
CHARLOTTE, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced the appointment of Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization, effective January 28. The appointment supports Dentsply Sirona's continued focus on strengthening commercial execution, deepening customer relationships and accelerating growth across the Americas. Mr. Bezjak is a seasoned commercial executive with more than 20 years of experience leading large-scale, multi-billion-dollar organizations in the medical device
CHARLOTTE, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Aldo M. Denti has been appointed Executive Vice President and Chief Commercial Officer (CCO), effective October 6, 2025. The appointment is designed to sharpen the Company's focus on the customer by aligning its Global Business Units and Commercial Organizations more closely - streamlining how Dentsply Sirona works and delivers. Mr. Denti is a global business leader with over 25 years of experience driving transformative growth in the Medical Device and Consumer Health sectors. His expertise spans sales, marketing, strategic planning, and successf
CHARLOTTE, N.C., May 29, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Matthew E. Garth has been appointed Executive Vice President and Chief Financial Officer, effective May 30, 2025. Mr. Garth brings nearly 30 years of proven financial management expertise to Dentsply Sirona, with a focus on driving value creation. He most recently served as Chief Financial Officer & Chief Administrative Officer of The Scotts Miracle-Gro Company, a global leader of branded consumer lawn and garden products. Prior to ScottsMiracle-Gro, Mr. Garth held numerous financial leadership roles at large, multinational companies, including Min
CHARLOTTE, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (XRAY) today announced that David Ferguson has been appointed Senior Vice President, Global Business Unit Leader, effective March 14, 2025. In this role he will lead the global business unit teams managing the dental product portfolio, serve as a member of the Executive Management Team and report directly to Chief Executive Officer, Simon Campion. David Ferguson joins Dentsply Sirona with 25 years of experience in MedTech and healthcare with a proven track record of delivering results, competing in a global marketplace and leading global product strategy. Mr. Ferguson has se
CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B
CHARLOTTE, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Herman V. Cueto, a seasoned healthcare executive, has been appointed Interim Chief Financial Officer, effective immediately. He brings over two decades of experience leading and working in finance organizations across the healthcare industry. Mr. Cueto will oversee the finance organization while Dentsply Sirona completes its ongoing search for the Company's next CFO. "We are fortunate to have Herman joining us as interim CFO during this important time in Dentsply Sirona's history," said Simon Campion, President and Chief Executive Officer. "Herman
Credo Technology Group Holding Ltd ("Credo" or the "Company") (NASDAQ:CRDO), an innovator in providing secure, high-speed connectivity solutions that deliver improved power efficiency as data rates and corresponding bandwidth requirements increase throughout the data infrastructure market, today announced the appointment of Clyde Hosein to the Company's board of directors effective April 3, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240401894812/en/Credo Technology Group Holding Ltd Announces Appointment of Industry Veteran Clyde Hosein to Board of Directors (Photo: Business Wire) "Clyde's appointment to the Credo boar
NEW YORK, March 27, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: Solventum Corp. (NYSE:SOLV) will be added to the S&P 500 effective prior to the open of trading on Monday, April 1, replacing V.F. Corp. (NYSE:VFC), which will be moved to the S&P SmallCap 600 effective prior to the open of trading on Wednesday, April 3. V.F. will replace ModivCare Inc. (NASD: MODV) in the S&P SmallCap 600 also effective prior to the open of trading on April 3. S&P 500 and 100 constituent 3M Co. (NYSE:MMM) is spinning off Solventum in a transaction expected to be completed April 1. Following the spin-off, the parent 3M will rema
CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Eric K. Brandt, who has served as a Director on the Company's Board of Directors (the "Board") for nearly twenty years and as Chairman of the Board for six years, has informed the Board of his intention to retire at the May 2024 annual meeting and that he will not be standing for re-election. Mr. Brandt commented, "As I think back on the past two decades and all of the challenges we've navigated together, I am grateful for the talented and dedicated individuals with whom I have had the privilege to serve. I am proud of the strong and diverse Boar
Live finance-specific insights
CHARLOTTE, N.C., Dec. 15, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on January 9, 2026, to holders of record as of December 26, 2025. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including den
Dentsply Sirona Reports Third Quarter 2025 Results Net sales of $904 million decreased (5.0%) as-reported, decreased (8.0%) in constant currency including (5.5%) driven by Q3 2024 Byte impact and ERP pre-buyGAAP gross margin of 48.8%, GAAP net loss per share of ($2.14)Adjusted gross margin of 52.6%, adjusted EBITDA margin of 18.4%, adjusted EPS of $0.37Revised FY25 outlook Executing its Return-to-Growth action plan to drive improved performance and deliver sustained, profitable growthProvides leadership updates to support transformation strategy CHARLOTTE, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its f
CHARLOTTE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, November 6, 2025, at 8:30 am ET to review its financial results for the third quarter of fiscal year 2025. The Company will issue a press release and provide a presentation with summary financial information, which will be made available on the Investors section of the Company's website at https://investor.dentsplysirona.com prior to the call. Conference Call / Webcast Information The live webcast will be available on the Investors section of the Company's website at
CHARLOTTE, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or "the Company") (NASDAQ:XRAY) today announced that Daniel Scavilla, an established business leader with more than three decades of experience in the medical technology and pharmaceutical industries and a current member of the Board of Directors of Dentsply Sirona (the "Board"), has been appointed President and Chief Executive Officer, effective August 1, 2025. He succeeds Simon Campion, who is leaving the Company on July 31, 2025. Mr. Scavilla recently served as President and Chief Executive Officer of Globus Medical, where he led the acquisition of NuVasive and oversaw the integration of the two
CHARLOTTE, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, August 7, 2025, at 8:30 am ET to review its financial results for the second quarter of fiscal year 2025. The Company will issue a press release and provide a presentation with summary financial information, which will be made available on the Investors section of the Company's website at https://investor.dentsplysirona.com prior to the call. Conference Call / Webcast Information The live webcast will be available on the Investors section of the Company's website at h
CHARLOTTE, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on July 11, 2025, to holders of record as of June 27, 2025. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and
Net sales of $879 million decreased (7.7%), organic sales decreased (4.4%) including a (4.0%) Byte sales impactGAAP gross margin of 53.0%, GAAP net income of $20 million or $0.10 per shareAdjusted gross margin of 56.3%, adjusted EBITDA margin of 19.0%, adjusted EPS of $0.43Maintaining FY25 outlook for organic sales and adjusted EPS; increasing reported sales due to F/X changes CHARLOTTE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial results for the first quarter of 2025. First quarter net sales of $879 million decreased (7.7%) (organic sales decreased (4.4%)) compared to the first quarter of 2
CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 8, 2025, at 8:30 am ET to review its first quarter financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. Conference Call / Webcast Information A live webcast will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register at https://register-conf
FY24 net sales of $3,793 million decreased (4.3%), organic sales decreased (3.5%) including a (1.2%) Byte sales impactFY24 GAAP net loss of ($910) million or ($4.48) per share, adjusted EPS of $1.67Q4 net sales of $905 million decreased (10.6%), organic sales decreased (10.7%) including a (6.0%) Byte sales impactQ4 GAAP net loss of ($430) million or ($2.16) per share, adjusted EPS of $0.26FY25 outlook: net sales in the range of $3.50 billion to $3.60 billion with organic sales down (4.0%) to (2.0%); adjusted EPS of $1.80 to $2.00(1) CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial resul
CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company has initiated a process to evaluate strategic alternatives for its Wellspect Healthcare business ("Wellspect"). Wellspect is a leading provider of bladder and bowel management care products with an over 40-year history. Through its comprehensive portfolio of products and accessories from trusted brands like LoFric® and Navina™, Wellspect has delivered improved organic sales growth in recent years, including mid-to-high single digit growth for 2023 and through the first three quarters of 2024. The business is well-positioned in the larg